

Bilbao, Spain

19 – 22 September 2025

12th Trends in Medical Mycology | www.timm2025.org



SCY-247 demonstrates high *in vitro* activity against genetically diverse *C. auris* isolates, including *FKS1* mutants

Eelco F.J. Meijer, MD, PhD, FECMM

Radboudumc-CWZ Center of Expertise for Mycology

Head section Mycology Canisius-Wilhelmina Hospital (CWZ)/Dicoon

ECMM Diamond Status Excellence Center

ECZA National Expertise Center for Rare Mycoses

RIVM Reference Center Invasive Mycoses

STZ registered center for Rare and Severe Mycoses

Eelco.Meijer@cwz.nl



Date of preparation: 17-9-2025

ECMM, European Confederation of Medical Mycology; ECZA, Expertisecentrum voor zeldzame aandoeningen;
RIVM, Rijksinstituut voor Volksgezondheid en Milieu; STZ, Samenwerkende Topklinische Ziekenhuizen

Bilbao, Spain

19 – 22 September 2025

12th Trends in Medical Mycology | www.timm2025.org



Disclosures




Disclosures	Companies
Research funding, Contracts, Speaker fees	- Mundipharma, Scynexis - Gilead Sciences - Pfizer Scientific Advisory Board

Bilbao, Spain

19 – 22 September 2025

12th Trends in Medical Mycology | www.timm2025.org

TIMM
Trends in Medical Mycology



C. auris and *in vivo* resistance

 **Mycoses**
Diagnosis, Therapy and Prophylaxis of Fungal Diseases

ORIGINAL ARTICLE |  Open Access |   

Whole genome sequencing analysis demonstrates therapy-induced echinocandin resistance in *Candida auris* isolates

Bram Spruijtenburg, Suhail Ahmad, Mohammad Asadzadeh, Wadha Alfouzan, Inaam Al-Obaid, Eiman Mokaddas, Eelco F. J. Meijer, Jacques F. Meis , Theun de Groot



► Euro Surveill. 2024 Nov 7;29(45):2400128. doi: [10.2807/1560-7917.ES.2024.29.45.2400128](https://doi.org/10.2807/1560-7917.ES.2024.29.45.2400128)

***Candida auris* fungaemia outbreak in a tertiary care academic hospital and emergence of a pan-echinocandin resistant isolate, Greece, 2021 to 2023**

[Joseph Meletiadi](#)¹, [Maria Siopi](#)¹, [Bram Spruijtenburg](#)^{2,3}, [Panagiota-Christina Georgiou](#)¹, [Maria Kostoula](#)⁴, [Irene Myrtilidou](#)⁵, [Irene Myrtilidou](#)⁶, [Irene Myrtilidou](#)⁷, [Jacques F Meis](#)^{3,8}, [Iraklis Tsangaris](#)⁶,

Eurosurveillance – in press

The rise of *Candida auris* in the Czech Republic: three clades, prosthetic joint infection and fluconazole resistance development

Bram Spruijtenburg^{1,2}, Jacques F. Meis^{1,3}, Norman van Rhijn^{4,5}, Martina Čurdová⁶, Eva Kašperová⁶, Petr Vašek⁷, Lucie Bartoníčková⁸, Jan Kubele⁹, Petra Olišarová¹⁰, [Kateřina Svobodová](#)¹⁰, [Daniela Lžičarová](#)¹¹, [Dana Němcová](#)⁹, [Věra Kůrková](#)¹², [Šárka Lásiková](#)¹³, [Naďa Mallátová](#)¹⁴, [Theun de Groot](#)^{1,2}, [Pavlaína Lysková](#)^{15*}, Eelco F.J. Meijer^{1,2*}

13655  **Clinical Microbiology and Infection**
Volume 28, Issue 6, June 2022, Pages 838-843

Original article

In vivo emergence of high-level resistance during treatment reveals the first identified mechanism of amphotericin B resistance in *Candida auris*

[Jeffrey M. Rybak](#)¹  , [Katherine S. Barker](#)¹, [José F. Muñoz](#)², [Josie E. Parker](#)³, [Suhail Ahmad](#)⁴, [Eiman Mokaddas](#)^{4,5}, [Aneesa Abdullah](#)⁵, [Rehab S. Elhagracy](#)⁶, [Steve L. Kelly](#)³, [Christina A. Cuomo](#)², [P. David Rogers](#)¹  


Bilbao, Spain

19 - 22 September 2025

12th Trends in Medical Mycology | www.timm2025.org



Background



→ **Triterpenoids**

- New antifungal class
- Inhibit 1,3-β-glucan biosynthesis
- Binding site different to EC

Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, Lass-Flörl C, Prattes J, Spec A, Thompson GR 3rd, Wiederhold N, Jenks JD. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. *Drugs*. 2021 Oct;81(15):1703-1729. doi: 10.1007/s40265-021-01611-0.



Background

- Ibrexafungerp; SCY-078
- First generation triterpenoid antifungal

TABLE 2.

In vitro activity of ibrexafungerp (IBX) and comparators against C. auris


Strain and agent	MIC (mg/liter)															MIC range(mg/liter)	Modal MIC (mg/liter)	MIC ₅₀ (mg/liter)
	≤0.004	0.008	0.016	0.03	0.06	0.125	0.25	0.5	1	2	4	8	16	32	≥64			
C. auris (n = 122)																		
IBX					1	3	33	63	20	2						0.06–2	0.5	0.5
ANF*			1	11	35	30	12	12	11	2	1	S639F		7		0.016→32	0.06	0.125
MCF*				5	30	70	9							8		0.03→32	0.125	0.125
AMB*								14	108							0.5–1	1	1
FLU*								1					2	10	109	0.5–≥64	≥64	≥64
VOR*	1			1	1	16	13	34	38	13	5					≤0.004–4	Bimodal	0.5
ISA*	20	1	1	19	9	19	21	21	6	5						≤0.004–2	Trimodal	0.125

12th Trends in Medical Mycology | www.timm2025.org

A diagram of a flower showing the arrangement of stamens and the central pistil. The stamens are arranged in a whorl around the central pistil, which is shown in cross-section.

[illegible]

- Second-generation triterpenoid antifungal
- Oral and IV
- Developed for better tissue penetration, GI tolerability and lower risk of drug-drug interactions



[Home](#) > [Mycopathologia](#) > [Article](#)

Short Tandem Repeat Genotyping of Medically Important Fungi: A Comprehensive Review of a Powerful Tool with Extensive Future Potential

Review | [Open access](#) | Published: 03 August 2024

Volume 189, article number 72, (2024) | [Cite this article](#)

[Download PDF](#)
✔ You have full access to this [open access](#) article



[Mycopathologia](#)

[Aims and scope](#) →

[Submit manuscript](#) →

[Bram Spruijtenburg](#), [Jacques F. Meis](#), [Paul E. Verweij](#), [Theun de Groot](#) & [Eelco F. J. Meijer](#) 

 747 Accesses  9 Altmetric | [Explore all metrics](#) →

[Use our pre-submission checklist](#)

Avoid common mistakes and increase your chances of publication with a pre-submission checklist.

Bilbao, Spain


19 – 22 September 2025

12th Trends in Medical Mycology | www.timm2025.org



Methods

- N=65 genetically diverse *C. auris* isolates
- Clades I-V
- EUCAST methodology
- Various *FKS1* mutants
 - Clade I, n=14, hotspot 1 and 3



Minimum-spanning tree of 65 *Candida auris* isolates
based on short tandem repeat genotyping

Bilbao, Spain

19 – 22 September 2025

12th Trends in Medical Mycology | www.timm2025.org




Figure 2: *In vitro* antifungal susceptibility testing of *Candida auris* against echinocandins and SCY-247

Bilbao, Spain

19 – 22 September 2025

12th Trends in Medical Mycology | www.timm2025.org



Conclusions

- SCY-247 demonstrates robust *in vitro* activity and differs from echinocandins in its efficacy to inhibit WT and FKS1 mutant isolates
- SCY-247 MICs are lower than echinocandins for all *FKS1* mutants *in vitro*
- PK/PD data and clinical trials



Radboudumc

